Keyphrases
Ovarian Cancer
100%
Homologous Recombination
100%
Genomic Instability
100%
Homologous Recombination Deficiency
85%
PARP Inhibitor (PARPi)
28%
High-grade Serous Ovarian Cancer (HGSOC)
28%
Routine Diagnostics
14%
Whole Genome Sequencing
14%
Illumina
14%
Clinical Setting
14%
Clinical Routine
14%
Molecular Assay
14%
Formalin-fixed Paraffin-embedded Tissue
14%
Mutation Status
14%
Bioinformatics pipeline
14%
OncoScan
14%
Tissue Block
14%
Interlaboratory Comparison
14%
European Medicines Agency
14%
Bioinformatics Algorithms
14%
Alternative Assays
14%
QiaSeq
14%
TSO500
14%
BRCA1, BRCA2
14%
Inhibitor Treatment
14%
Medicine and Dentistry
Genomic Instability
100%
Homologous Recombination
100%
Ovarian Cancer
100%
Biological Marker
28%
PARP Inhibitor
28%
Clinical Study
14%
Diagnosis
14%
Medicine
14%
BRCA1
14%
Formaldehyde
14%
Whole Genome Sequencing
14%
Biochemistry, Genetics and Molecular Biology
Genome Instability
100%
Homologous Recombination
100%
Poly ADP Ribose Polymerase
28%
Bioinformatics
28%
Clinical Study
14%
BRCA1
14%
Whole Genome Sequencing
14%
Pharmacology, Toxicology and Pharmaceutical Science
Ovary Cancer
100%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
50%
Biological Marker
50%
Formaldehyde
25%
Clinical Study
25%
Immunology and Microbiology
Genomic Instability
100%
Homologous Recombination
100%
Bioinformatics
28%
Whole Genome Sequencing
14%